LNSRLENSAR, Inc.vs its industry peers
A metric-by-metric comparison of LENSAR, Inc. against Surgical & Medical Instruments & Apparatus — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LNSRThis | $86M#8 | 35.0x#3 | 5.8x#9 | 1.7x#6 | 12.4%#5 | -9.2%#10 | -47.6%#8 | -230.0%#10 | — | — | -43.2%#11 | — |
| LUCD | $156M#1 | — | 14.3x#13 | 33.1x#13 | 8.3%#8 | -27.4%#12 | -1054.8%#13 | -530.9%#12 | — | 3#6 | -28.7%#9 | — |
| KRMD | $149M#2 | — | 8.2x#10 | 3.6x#12 | 22.2%#3 | 56.5%#3 | -7.2%#3 | -14.6%#2 | -29.4%#4 | 6#2 | -20.2%#6 | — |
| APYX | $127M#3 | — | 12.0x#12 | 2.4x#8 | 9.9%#7 | 52.2%#4 | -12.2%#4 | -105.1%#7 | -23.6%#3 | 6#2 | 36.9%#1 | — |
| GUTS | $94M#4 | — | — | — | -100.0%#15 | -105.2%#14 | — | — | — | — | -39.2%#10 | — |
| MBOT | $93M#5 | — | 1.3x#3 | 793.0x#15 | -88.5%#14 | -14.8%#11 | -12613.0%#14 | -19.1%#4 | -22.4%#2 | 5#4 | -55.3%#12 | — |
| SKIN | $89M#6 | — | 1.6x#5 | 0.3x#1 | -10.0%#10 | 67.4%#2 | -6.9%#2 | -17.1%#3 | — | — | -71.1%#15 | — |
| LUNG | $88M#7 | — | 2.2x#6 | 1.0x#3 | 8.0%#9 | 4.2%#7 | -59.3%#9 | -137.8%#8 | -257.0%#7 | 3#6 | 28.9%#2 | — |
| CVRX | $78M#9 | — | 3.9x#7 | 1.4x#5 | 10.4%#6 | 11.1%#6 | -90.5%#11 | -267.2%#11 | -296.8%#9 | 3#6 | -59.3%#13 | — |
| SKYA | $73M#10 | — | 0.5x#1 | 355.9x#14 | — | -2938.9%#16 | -132145.5%#15 | -179.6%#9 | -181.9%#6 | — | -79.3%#16 | — |
| DRIO | $68M#11 | 1.3x#1 | 1.2x#2 | 3.0x#11 | -17.3%#11 | 2.4%#8 | -163.9%#12 | -75.7%#6 | -41.6%#5 | 3#6 | 2.4%#4 | — |
| TLSIW | $55M#12 | — | 8.5x#11 | 1.2x#4 | 53.4%#1 | -30.6%#13 | -59.7%#10 | -598.9%#13 | — | 5#4 | -61.7%#14 | — |
| TELA | $54M#13 | — | — | 0.7x#2 | 15.8%#4 | -2.6%#9 | -42.0%#6 | — | -257.2%#8 | 3#6 | -24.1%#7 | — |
| MDAI | $52M#14 | — | — | 2.6x#10 | -33.6%#12 | 50.1%#5 | -43.8%#7 | — | — | 3#6 | -27.6%#8 | — |
| SRTS | $50M#15 | — | 1.4x#4 | 1.8x#7 | -34.3%#13 | -216.1%#15 | -37.5%#5 | -20.9%#5 | — | — | -3.5%#5 | — |
| NEPH | $48M#16 | 27.6x#2 | 5.7x#8 | 2.6x#9 | 32.7%#2 | 1513.5%#1 | 6.1%#1 | 14.3%#1 | 26.8%#1 | 7#1 | 2.7%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3841). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice